Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 -0.635M
March 31, 2026 -5.642M
December 31, 2025 -0.335M
September 30, 2025 -5.258M
June 30, 2025 -0.887M
March 31, 2025 -0.406M
December 31, 2024 -2.767M
September 30, 2024 0.113M
June 30, 2024 -0.905M
March 31, 2024 -6.024M
December 31, 2023 -0.481M
September 30, 2023 -0.649M
June 30, 2023 -0.348M
March 31, 2023 -0.677M
December 31, 2022 -1.709M
September 30, 2022 -0.374M
June 30, 2022 -0.429M
March 31, 2022 -0.148M
December 31, 2021 -0.314M
September 30, 2021 -0.58M
June 30, 2021 -0.422M
March 31, 2021 -2.079M
December 31, 2020 -2.273M
September 30, 2020 -0.71M
June 30, 2020 -0.486M
Date Value
March 31, 2020 -1.086M
December 31, 2019 -0.793M
September 30, 2019 2.06M
June 30, 2019 -0.33M
March 31, 2019 -0.433M
December 31, 2018 -1.186M
September 30, 2018 -2.453M
June 30, 2018 -2.474M
March 31, 2018 -3.107M
December 31, 2017 -1.255M
September 30, 2017 -1.394M
June 30, 2017 -1.779M
March 31, 2017 -0.969M
December 31, 2016 -1.295M
September 30, 2016 -1.734M
June 30, 2016 0.573M
March 31, 2016 -9.286M
December 31, 2015 1.592M
September 30, 2015 -1.105M
June 30, 2015 -0.117M
March 31, 2015 -1.048M
December 31, 2014 -9.845M
September 30, 2014 -0.8732M
June 30, 2014 -0.8004M
March 31, 2014 -0.6337M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. -1.28M
Perspective Therapeutics, Inc. 15.02M
ABVC BioPharma, Inc. -0.1015M
Enovis Corp. -45.01M
Edwards Lifesciences Corp. -193.20M